<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatic manifestations of sickle cell disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatic manifestations of sickle cell disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatic manifestations of sickle cell disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Subhas Banerjee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R DeBaun, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sickle cell disease (SCD) encompasses a group of hemoglobinopathies characterized by a single amino acid substitution in the beta-globin chain. The most frequently occurring form of SCD is sickle cell anemia (HbSS), followed by sickle-hemoglobulin C (HbSC) and sickle-beta (HbS/beta)-thalassemia. In SCD the majority of the hemoglobin (greater than 50 percent) is hemoglobin S. In the United States, 6 to 10 percent of African-American newborns have sickle cell trait (HbSA), and approximately 0.2 percent have sickle cell anemia (HbSS) [<a href="#rid1">1</a>]. Sickle cell trait (HbSA) is not considered SCD. (See  <a class="medical medical_review" href="/d/html/7127.html" rel="external">"Hemoglobin variants including Hb C, Hb D, and Hb E"</a>.)</p><p>The liver can be affected by a number of complications due to SCD. In addition to the vascular complications from the sickling process, patients with SCD have often received multiple transfusions, placing them at risk for viral hepatitis, iron overload, and (combined with the effects of chronic hemolysis) the development of pigment gallstones, all of which may contribute to the development of liver disease. (See  <a class="medical medical_review" href="/d/html/3675.html" rel="external">"Epidemiology and transmission of hepatitis C virus infection", section on 'Blood transfusion'</a> and  <a class="medical medical_review" href="/d/html/3630.html" rel="external">"Epidemiology, transmission, and prevention of hepatitis B virus infection", section on 'Transfusion'</a> and  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.) </p><p>The term "sickle cell hepatopathy" has sometimes been used to reflect the overlapping causes of liver dysfunction in individuals with SCD, not SCT. Sickle cell hepatopathy occurs predominantly in patients with homozygous sickle cell anemia, and to a lesser extent in patients with HbSC disease or HbS/beta-thalassemia.</p><p>This topic will review the hepatic manifestation of SCD. Clinical manifestations, management, and prognosis of SCD are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The overall incidence of liver disease in patients with sickle cell disease (SCD) has not been well established. The major risk factor for liver disease in patients with SCD is receiving multiple blood transfusions, which is associated with infection (hepatitis B virus [HBV] infection and hepatitis C virus [HCV] infection) and excessive iron stores.</p><p>In one report, 32 of 100 patients had abnormal liver biochemical tests during a five-year follow-up period [<a href="#rid2">2</a>]. In an autopsy series, hepatomegaly was noted in 91 percent of 70 patients with sickle cell anemia or others forms of SCD, suggesting that some form of liver involvement is common [<a href="#rid3">3</a>]. In other autopsy series, 16 to 29 percent of patients had cirrhosis [<a href="#rid3">3-6</a>]. However, it is unclear whether cirrhosis was due to the sickle cell anemia itself or to concurrent liver disease acquired as a consequence of multiple transfusions, leading to excessive iron overload and/or chronic HBV or HCV infection.</p><p class="headingAnchor" id="H3"><span class="h1">LABORATORY AND RADIOLOGIC LIVER TESTS</span><span class="headingEndMark"> — </span>Biochemical and radiologic hepatic abnormalities are common in individuals with sickle cell disease (SCD). A major risk factor for liver biochemical abnormalities in patients with SCD is infection (hepatitis B virus [HBV] infection or hepatitis C virus [HCV] infection) or excessive iron stores related to multiple blood transfusions. (See  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Biochemical tests</span><span class="headingEndMark"> — </span>Elevated bilirubin levels, predominantly unconjugated, are universal in patients with SCD due to chronic hemolysis. Total bilirubin concentrations are usually &lt;6 mg/dL (102.6 micromoles/L), but may double during sickle hepatic crises [<a href="#rid7">7</a>]. In one series, 72 of 100 patients with sickle cell anemia had an isolated elevation of bilirubin, with no other clinical or laboratory evidence of liver disease [<a href="#rid2">2</a>]. Bilirubin levels correlated with lactic dehydrogenase levels, suggesting that variable levels found in patients are related to the degree of hemolysis, ineffective erythropoiesis or both, rather than to disorders of bilirubin transport or processing. The serum aspartate aminotransferase level (AST) is also raised by hemolysis. Thus, AST levels correlate with lactic dehydrogenase levels, while serum alanine aminotransferase (ALT) levels may more accurately reflect hepatocyte injury [<a href="#rid2">2</a>].</p><p>Elevation of the serum alkaline phosphatase is common, particularly during pain crises. However, bone alkaline phosphatase is the major enzyme fraction contributing to this rise [<a href="#rid8">8</a>]. This is supported by the observation that the serum-5' nucleotidase concentration correlates with the ALT and gamma glutamyl transferase levels, but not with alkaline phosphatase levels [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/3612.html" rel="external">"Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"</a>.)</p><p>Acute elevations of the serum ALT and AST are seen in the setting of vaso-occlusive episodes leading to hepatic ischemia, whereas chronic liver function test abnormalities are usually due to coexisting hepatic pathology. In a study of 130 patients with sickle cell anemia or SCD, chronic abnormalities in liver function tests were found in 32 patients [<a href="#rid2">2</a>]. In 30 of these patients, the abnormalities could be explained by coexisting liver pathology, including chronic hepatitis B virus infection, common bile duct obstruction, and alcohol use. Only two patients had unexplained abnormalities, neither of whom had been tested for antibodies against HCV. In another series of 121 consecutive patients with sickle cell anemia, 11 (9 percent) had chronically raised ALT levels. Of these, nine patients were positive for HCV antibodies and one patients was positive for hepatitis B surface antigen (HBsAg) [<a href="#rid10">10</a>].</p><p>Several studies have demonstrated low protein C and protein S levels in patients with sickle cell anemia [<a href="#rid11">11-13</a>]. It is unclear whether decreased levels of protein C and S were primarily due to decreased hepatic production, or were a consequence of increased consumption. Low levels of protein C and S may increase the risk of stroke [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/1354.html" rel="external">"Protein C deficiency"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Zinc deficiency</span><span class="headingEndMark"> — </span>Patients with sickle cell anemia excrete excessive amounts of zinc due to impaired renal tubular handling [<a href="#rid14">14,15</a>], which may lead to zinc deficiency. <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">Deferoxamine</a> therapy may also increase urinary and fecal losses of zinc [<a href="#rid16">16</a>]. A study of 104 patients with sickle cell disease indicated that 44 percent had low plasma levels of zinc [<a href="#rid17">17</a>]. </p><p>Zinc is a cofactor for ornithine transcarbamylase, a urea cycle enzyme [<a href="#rid18">18</a>]. Thus, zinc deficiency may be associated with inhibition of the urea cycle and hyperammonemia [<a href="#rid19">19</a>]. </p><p>Data have been accumulating that zinc deficiency is associated with multiple morbidities in SCD, such as increased risk of vaso-occlusive pain [<a href="#rid20">20</a>] and infections [<a href="#rid21">21,22</a>], and decreased prepubertal linear growth and weight gain [<a href="#rid17">17,23,24</a>]. Zinc may also regulate copper absorption from the gastrointestinal tract. Enhanced copper absorption and increased ceruloplasmin levels may be seen with zinc deficiency [<a href="#rid19">19,25</a>].</p><p>If zinc supplementation is given, copper levels should be assessed annually because zinc interferes with gastrointestinal absorption of copper. </p><p>Whether zinc supplementation reduces the risk of zinc deficiency in patients with SCD is not known. Zinc supplementation in SCD is not typically done, but the lack of published data does not preclude treatment on a case-by-case basis. The daily requirements for zinc and management of zinc deficiency are discussed separately  (<a class="graphic graphic_table graphicRef51953" href="/d/graphic/51953.html" rel="external">table 1</a>) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Liver histology</span><span class="headingEndMark"> — </span>Percutaneous liver biopsy has been associated with serious complications when performed in individuals with SCD with acute hepatic disease [<a href="#rid27">27</a>]. Thus, the risk-benefit ratio of obtaining the liver histology must be strongly considered, particularly in light of how the results will alter management. Liver histology can be used to determine hepatic iron content. However, we typically do not perform a liver biopsy for assessment of hepatic iron in individuals with SCD. We reserve liver biopsy for individuals with SCD in whom magnetic resonance imaging (MRI)-based estimates of liver iron content are inconsistent with the transfusion history, or where there is concern regarding liver function, and we want to assess histology of the liver. Further, significant variability of the liver iron content may occur within the liver, such that a single needle biopsy may not be representative of the total iron content in the liver [<a href="#rid28">28</a>]. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p>When obtained, liver histology may reflect changes of concurrent chronic viral hepatitis, cholestasis due to common bile duct stones, and features primarily due to the sickle cell anemia itself. Histologic features due to sickle cell anemia include intrasinusoidal sickling with proximal sinusoidal dilatation, Kupffer cell hyperplasia with erythrophagocytosis, and hemosiderosis [<a href="#rid3">3,5,29-31</a>]. The following findings were observed in a postmortem series of 70 patients [<a href="#rid3">3</a>]: sinusoidal red blood cell distension (71 percent), Kupffer cell erythrophagocytosis (91 percent), iron deposition (47 percent), focal necrosis (35 percent), portal fibrosis (20 percent), regenerative nodules (20 percent), and cirrhosis (16 percent).</p><p>Other histologic features may reflect the clinical setting. Mild centrilobular necrosis has been described in patients with sickle hepatic crises [<a href="#rid7">7</a>]. Widespread anoxic necrosis was seen in two post-mortem biopsies in patients with sickle cell intrahepatic cholestasis [<a href="#rid7">7,32</a>]. Other findings that may be seen on liver biopsy include perisinusoidal fibrosis, peliosis hepatis [<a href="#rid33">33</a>], and extramedullary erythropoiesis [<a href="#rid34">34</a>].</p><p>The degree of intrasinusoidal sickling does not correlate with the serum aminotransferase concentrations [<a href="#rid2">2,31,35</a>]. It is possible that some of the sickling observed in liver biopsy specimens results from fixation with formaldehyde, which in one study increased the sickle cell count from a mean of 12 to 48 percent [<a href="#rid2">2</a>].</p><p>The relationship between liver fibrosis and excessive iron stores has not been well defined. In a retrospective study in individuals with SCD who were receiving regular blood transfusion therapy over a median of 8.4 years (range 2.3 to 24 years), predictors of liver fibrosis were assessed [<a href="#rid36">36</a>]. A total of 26 individuals had at least two liver biopsies, with an average of two years between the first and second biopsy. Each biopsy was scored for fibrosis in a blinded fashion. The primary outcome was assessment of changes in liver fibrosis. Liver fibrosis was rated as grade 0 or 1 in all biopsies. Between the first and second biopsy, there was fibrosis regression in six individuals, development of fibrosis in two patients, persistent fibrosis in one patient, and absence of fibrosis in 17 patients. No association between fibrosis and liver iron content was observed. </p><p>Eight individuals had MRI assessment of liver iron content within three months of a liver biopsy. Liver iron content in these individuals did not have any correlation with liver fibrosis. Although this retrospective study has limitations, these data suggest that natural history and risk factors for fibrosis in individuals with SCD receiving regular blood transfusions are poorly understood.</p><p class="headingAnchor" id="H7"><span class="h2">Imaging tests</span><span class="headingEndMark"> — </span>Imaging tests are frequently abnormal in patients with SCD.</p><p class="headingAnchor" id="H8"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>Computed tomography (CT) scanning in patients with HbSS usually reveals diffuse hepatomegaly, possibly a reflection of expansion of the hepatic reticuloendothelial system. The spleen is usually small and atrophic and may have dense calcifications, often due to repeated splenic infarction. Compound heterozygotes (ie, HbSC and HbS beta-thalassemia) usually have splenomegaly and may have infarcts, splenic rupture from extensive infarction and necrosis, hemorrhage, abscess, and acute splenomegaly due to sequestration. A CT scan of the abdomen may also incidentally reveal basal pulmonary pathology, especially in patients presenting with abdominal pain. (See  <a class="medical medical_review" href="/d/html/7121.html" rel="external">"Overview of the pulmonary complications of sickle cell disease"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Given the advancement in the use of MRI methods to evaluate liver iron, MRI's reliability, and its noninvasive nature, MRI imaging has become the standard approach for assessing liver iron stores in individuals with SCD who are chronically transfused [<a href="#rid37">37</a>]. Many centers use commercial software to quantify liver iron stores, particularly in such patients. MRI in transfusion dependent patients usually shows decreased signal intensity in the liver and pancreas due to iron deposition [<a href="#rid38">38-41</a>]. (See  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Ultrasound</span><span class="headingEndMark"> — </span>Abdominal ultrasound in individuals with SCD is likely to reveal gallstones and increased echogenicity of the liver and pancreas due to iron deposition [<a href="#rid39">39</a>]. </p><p class="headingAnchor" id="H11"><span class="h1">DISORDERS ASSOCIATED WITH THE SICKLING PROCESS</span><span class="headingEndMark"> — </span>Liver disease in individuals with sickle cell disease (SCD) can be conceptually divided into disorders caused by the sickling process, and those resulting from complications of the disease or its treatment [<a href="#rid42">42</a>]. However, the distinction between these two categories is not always clear because they often exist concurrently. Furthermore, studies describing liver disease in this population often omitted secondary causes of liver disease such as hepatitis C virus infection. Thus, the relative contribution of these coexisting conditions to the clinical presentation has not always been clear.</p><p class="headingAnchor" id="H12"><span class="h2">Acute pain and jaundice</span><span class="headingEndMark"> — </span>Acute presentation with pain and jaundice may be due to several different causes that may coexist. These include acute sickle hepatic crisis, sickle cell intrahepatic cholestasis, acute viral hepatitis, cholecystitis, and choledocholithiasis with common bile duct obstruction. The diagnosis can usually be established by the medical history and specific laboratory and radiologic testing.</p><p class="headingAnchor" id="H13"><span class="h3">Acute sickle cell hepatic crisis</span><span class="headingEndMark"> — </span>Acute sickle cell hepatic crisis has been observed in approximately 10 percent of adult patients with SCD [<a href="#rid7">7,43,44</a>]. Patients usually present with acute right upper quadrant pain, nausea, low grade fever, tender hepatomegaly, and elevated bilirubin levels, predominantly conjugated fraction [<a href="#rid7">7,43,44</a>]. The serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations are seldom &gt;300 international units/L [<a href="#rid7">7,44</a>], although levels &gt;1000 international unit/L have been described [<a href="#rid29">29</a>]. The serum total bilirubin concentration is usually &lt;15 mg/dL (256.5 micromoles/L) [<a href="#rid7">7</a>]. Liver histology may reveal sickle cell thrombi in the sinusoidal space with engorgement by red blood cells. Other features that have been described include Kupffer cell hypertrophy, mild centrilobular necrosis, and occasional bile stasis [<a href="#rid7">7</a>].</p><p>The pathogenesis is probably related to ischemia caused by sinusoidal obstruction. This hypothesis is supported by the observation that cocaine use by patients with sickle cell anemia can precipitate severe and life-threatening crisis due to synergistic hypoxic injury from cocaine-induced vasospasm and from sickling [<a href="#rid45">45</a>].</p><p>Supportive treatment with intravenous hydration and analgesia is usually sufficient. Symptoms and laboratory abnormalities usually resolve within 3 to 14 days.</p><p>In children with SCD, hepatic crisis is typically a self-limiting course recognized with total bilirubin levels as high as 57.6 g/dL with 50 percent being fractionated.</p><p class="headingAnchor" id="H16"><span class="h3">Sickle cell intrahepatic cholestasis</span><span class="headingEndMark"> — </span>Sickle cell intrahepatic cholestasis represents a severe variant of sickle cell hepatic crisis. It is due to disseminated vaso-occlusion in the sinusoids, with hepatic ischemia and a possible evolution towards multiple organ failure [<a href="#rid46">46</a>]. Hypoxic damage leads to ballooning of hepatocytes and intracanalicular cholestasis.</p><p>The presentation is initially similar to that seen with acute sickle hepatic crises, with right upper quadrant pain, nausea and vomiting, fever, tender hepatomegaly, and leukocytosis. However, striking jaundice then develops, accompanied frequently by renal impairment, a bleeding diathesis, and increasing encephalopathy.</p><p>In various reports, serum ALT levels have ranged from 34 to 3137 international units/L, serum AST levels from 100 to 9881 international units/L, and alkaline phosphatase levels have ranged from normal to 860 international units/L. Total serum bilirubin levels may be strikingly high; levels of up to 273 mg/dL (4668.3 micromoles/L) have been observed [<a href="#rid47">47</a>]. In most cases, the conjugated fraction exceeds 50 percent of the total bilirubin [<a href="#rid48">48</a>]. The extremely high bilirubin levels are due to a combination of ongoing hemolysis, intrahepatic cholestasis, and renal impairment. LDH levels are usually elevated in the range of 660 to 7760 international units/L. Prolongation of the prothrombin and partial thromboplastin time is common. Elevations in blood urea, creatinine, and ammonia are also seen. Hypofibrinogenemia, thrombocytopenia, and lactic acidosis may accompany liver failure [<a href="#rid47">47</a>].</p><p>Postmortem liver biopsies in four patients with sickle intrahepatic cholestasis showed dilated canaliculi with bile plugs [<a href="#rid4">4,7,32,49</a>]. Scattered bile stained microinfarcts were seen in one of these biopsies [<a href="#rid49">49</a>], while widespread anoxic necrosis with areas of acute and chronic inflammation, in addition to the usual findings noted in sickle cell patients, were seen in the other three biopsies [<a href="#rid4">4,7,32</a>]. (See <a class="local">'Liver histology'</a> above.)</p><p>At least 17 probable cases have been described [<a href="#rid4">4,7,32,47,49-55</a>]. The syndrome was fatal in nine early cases; other reports have described reversal of this process within 48 hours in eight patients, with vigorous exchange transfusions and correction of coagulopathy with fresh frozen plasma [<a href="#rid32">32,47,50,52-55</a>]. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Simple versus exchange transfusion'</a> and  <a class="medical medical_review" href="/d/html/7920.html" rel="external">"Clinical use of plasma components", section on 'Plasma products'</a>.)</p><p>The renal impairment in sickle intrahepatic cholestasis has not been well studied, but appears to be reversible and improves concurrently with hepatic improvement [<a href="#rid32">32,53,55</a>]. Urine electrolytes were measured in a single case and suggested acute tubular necrosis [<a href="#rid53">53</a>], but the authors attributed this to the patient's aminoglycoside therapy. Renal ultrasound done in a single case demonstrated mildly altered corticomedullary differentiation [<a href="#rid47">47</a>]. Multiple focal acute renal infarcts were described on gross examination in a single case at postmortem [<a href="#rid7">7</a>]. Renal histology was done in a single patient postmortem and showed numerous hemoglobin casts in the distal convoluted tubules [<a href="#rid51">51</a>]. Hemodialysis was instituted in two patients for anuria [<a href="#rid32">32,55</a>], and peritoneal dialysis was carried out in another patient for refractory hyperkalemia [<a href="#rid7">7</a>]. Two of these patients succumbed to their illness, but one of the patients treated with hemodialysis survived. (See  <a class="medical medical_review" href="/d/html/7199.html" rel="external">"Sickle cell disease effects on the kidney"</a>.)</p><p>Optimal management of hepatic crises has not been elucidated. However, a reasonable strategy has been to consider initial simple blood transfusion, particularly if there is a drop in hemoglobin greater than 2 g/dL, or evidence of hemodynamic instability (increased pulse rate, increased work of breathing, decreased hemoglobin oxygen saturation). If there is limited or no improvement in liver disease, then automated exchange transfusion should be considered the next intervention [<a href="#rid42">42</a>].  </p><p class="headingAnchor" id="H2634744794"><span class="h3">Acute hepatic sequestration</span><span class="headingEndMark"> — </span>Acute hepatic sequestration is defined as the sudden increase in liver size, associated with right upper quadrant abdominal pain, and an acute decrease in hemoglobin level &gt;2 g/dL; thrombocytopenia and normal or increased reticulocyte count increased conjugated bilirubin level and liver failure. Hepatic sequestration is well-recognized complication of SCD associated with inability of red blood cells in the liver to circulate, hence the term sequestration [<a href="#rid56">56</a>]. Patients with hepatic sequestration usually present with right upper quadrant pain, rapidly increasing hepatomegaly, and a falling hematocrit [<a href="#rid56">56,57</a>]. One report described two patients with hepatic sequestration who initially presented with bone pain [<a href="#rid56">56</a>]. A rapid fall in the hematocrit paralleled a dramatic increase in the liver size, which returned to baseline after three to four days. Liver biochemical tests did not substantially change. Regression of hepatic size was associated with a rapid increase in hemoglobin from 4.2 to 7.5 g/dL in one patient, indicating that not all sequestered cells were destroyed, and that some may return to the circulation upon resolution of the crisis and relief of sinusoidal obstruction. The management of hepatic sequestration is focused on hemodynamic and cardiopulmonary stability. If there is hemodynamic or cardiopulmonary instability (eg, congestive heart failure, postural hypotension, tachycardia, increased respiratory effort, altered mental status), a simple transfusion should be given. However, only small aliquots of red blood cell transfusions should be given to decrease the chance of autotransfusion, a process where cells sequestered in the spleen, lung, liver are suddenly released and that results in hyperviscosity syndrome [<a href="#rid58">58</a>]. A case of fatal auto-transfusion was described in which resolution of hepatic and pulmonary sequestration was accompanied by a spontaneous and rapid rise in the hemoglobin, from 5.1 to 12.3 g/dL over 24 hours, presumably from the release of viable sequestered cells back into the circulation [<a href="#rid58">58</a>]. Death occurred from the resultant hypervolemia, hypertension, heart failure, and intracerebral hemorrhage. </p><p>For adults with hepatic sequestration with hemodynamic or cardiopulmonary instability, we give one unit of packed red blood cells. For children with hepatic sequestration, we give 5 cc/kg of packed red blood cells. After transfusion, if the patient has clinically improved, no further transfusion is needed [<a href="#rid59">59,60</a>]. Following transfusion, patients should have their posttransfusion hemoglobin levels monitored closely (at least daily for several days following the transfusion or more frequently if the patient is symptomatic). If there is an abrupt rise in hemoglobin concentration to above 11 g/dL, consideration should be made for phlebotomy. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques"</a>.)</p><p class="headingAnchor" id="H17"><span class="h4">Benign hyperbilirubinemia</span><span class="headingEndMark"> — </span>In contrast with the severe cholestasis, marked "benign" predominantly conjugated hyperbilirubinemia of up to 57 mg/dL (974.7 micromoles/L) with only a mild elevation in serum ALT has been described in children and adults who had minimal or no symptoms [<a href="#rid2">2,61</a>]. The hyperbilirubinemia resolved spontaneously within two to eight weeks with no subsequent recurrences. It is possible that these cases represent a benign variant of intrahepatic cholestasis.</p><p class="headingAnchor" id="H18"><span class="h4">Chronic intrahepatic cholestasis</span><span class="headingEndMark"> — </span>A case report described a patient with sickle cell anemia and very high bilirubin levels of &gt;88 mg/dL (1504.8 micromoles/L) due to chronic intrahepatic cholestasis [<a href="#rid62">62</a>]. He had no abdominal pain and no hematological evidence of increased hemolysis. He responded dramatically to an exchange transfusion, with his bilirubin falling to 10 mg/dL. He developed repeated episodes of hyperbilirubinemia during a three-year follow-up, requiring regular exchange transfusions to keep his hemoglobin S levels &lt;20 percent to prevent recurrent intrahepatic cholestasis.</p><p class="headingAnchor" id="H19"><span class="h1">DISORDERS RELATED TO COEXISTING CONDITIONS</span></p><p class="headingAnchor" id="H20"><span class="h2">Cholelithiasis</span><span class="headingEndMark"> — </span>The prevalence of pigmented gallstones in sickle cell disease (SCD) is directly related to the rate of hemolysis [<a href="#rid63">63,64</a>]. Gallstones occur in children as young as three to four years of age, and the incidence increases with age, reaching 50 percent by the age of 22 years. Gallstones are eventually found in approximately 70 percent of older adults with SCD [<a href="#rid65">65-69</a>]. Genetic variation contributes to the risk of cholelithiasis in SCD. Individuals with a higher rate of SCD-related hemolysis have a higher rate of cholelithiasis. In an observational study including 131 patients with SCD, gallstones were detected by ultrasound or at cholecystectomy in 58 percent of patients with HbSS, 17 percent of patients with HbSC, and 17 percent of patients with beta-thalassemia [<a href="#rid63">63,68</a>]. The presence of alpha-thalassemia gene deletion when compared with those without alpha-thalassemia in SCD is associated with a lower incidence of cholelithiasis. Genetic variance of uridine diphosphate glucuronosyltransferase 1 has been associated with cholelithiasis [<a href="#rid70">70</a>], an increase in mean serum bilirubin levels [<a href="#rid71">71</a>] and increased symptomatic cholelithiasis risk in SCD and in Gilbert syndrome [<a href="#rid70">70,72</a>], a disease associated with increased unconjugated hyperbilirubinemia. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a>.) </p><p>The approach to screening patients with SCD varies among centers, and routine evaluations for patients with SCD are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease", section on 'Routine evaluations and treatments'</a> and  <a class="medical medical_review" href="/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a>.) </p><p>Most patients with gallstones are asymptomatic, and observation of such patients has been supported by expert consensus [<a href="#rid59">59,60,73</a>]. Risks that have been associated with elective surgery include risk of postoperative, life-threatening acute chest syndrome, and need for red blood cell transfusions [<a href="#rid74">74-76</a>].</p><p>However, observational data have suggested the cholecystectomy was common in patients with SCD. In a study of 509 adult patients with SCD, the reported rates of cholecystectomy for patients 18 to 47 years of age and for patients ≥47 years of age were 48 and 69 percent, respectively [<a href="#rid64">64</a>].</p><p>The clinical presentation of acute cholecystitis and sickle hepatic crisis can be similar. Biliary scintigraphy may be useful in ruling out acute cholecystitis, although it is not always diagnostic [<a href="#rid77">77</a>]. Elective cholecystectomy should be considered in patients with symptomatic gallstones, and in patients in whom gallstone related symptomatology cannot be differentiated from sickle cell hepatic crises [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/d/html/666.html" rel="external">"Acute calculous cholecystitis: Clinical features and diagnosis", section on 'Diagnostic approach'</a>.)</p><p>After a decision is made to perform cholecystectomy, the preferred surgical strategy is a laparoscopic procedure. Laparoscopic cholecystectomy is performed because it has been associated with a shorter hospital length of stay and lower rates of postoperative complications, although it has not reduced the risk of sickle cell-related complications compared with open cholecystectomy [<a href="#rid78">78-80</a>].</p><p>We routinely give simple blood transfusion for individuals with HbSS with hemoglobin less than 9 g/dL undergoing cholecystectomy, with the goal of raising the hemoglobin to approximately 10 g/dL. The efficacy of preoperative simple transfusion in preventing potentially life-threatening acute chest syndrome and other complications, as well as other perioperative issues, are discussed separately. (See  <a class="medical medical_review" href="/d/html/90145.html" rel="external">"Red blood cell transfusion in sickle cell disease: Indications and transfusion techniques", section on 'Prophylactic preoperative transfusion'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Excessive iron stores</span><span class="headingEndMark"> — </span>The likelihood of developing excessive iron stores is a direct function of the number of blood transfusions received. In patients with sickle cell anemia, serum ferritin levels correlate with the number of units of blood transfused [<a href="#rid81">81</a>]. Rises in serum ferritin occur during painful vaso-occlusive sickle crises [<a href="#rid82">82</a>], and hence steady state ferritin levels provide a better estimate of the degree of iron overload [<a href="#rid81">81</a>]. In one study, automated red blood cell exchange, an isovolumetric process, was associated with lower ferritin levels compared with simple and manual exchange transfusions [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>.)</p><p>In individuals with SCD who have received multiple transfusions, increased deposition of iron occurs within reticuloendothelial cells, including Kupffer cells. The correlation of plasma steady state ferritin levels with hepatic iron stores is not known precisely [<a href="#rid84">84-87</a>]. However, at least two studies found a poor correlation of plasma ferritin with hepatic iron stores as determined by liver biopsy in patients who were receiving chronic transfusions [<a href="#rid86">86,87</a>].</p><p>In individuals with SCD, data on histologic progression to fibrosis with excessive iron stores have been limited. In an autopsy series of 70 patients with sickle cell anemia and sickle beta-thalassemia, 33 patients were found to have variable degrees of parenchymal iron deposition [<a href="#rid3">3</a>]. Cirrhosis was seen in three of these patients, and parenchymal iron accumulation was considered to be severe enough to make a diagnosis of hemochromatosis as the etiology for the cirrhosis. However, hepatic iron content was not determined on biopsy, and other etiologies contributing to the cirrhosis were not excluded. </p><p>Another series focused on 11 individuals with HbSS who were followed over 5 to 10 years, during which time they received a mean of 180 units of packed red blood cells together with an intravenous chelating agent, <a class="drug drug_general" data-topicid="9327" href="/d/drug information/9327.html" rel="external">deferoxamine</a> (2 g), with each transfusion [<a href="#rid88">88</a>]. Despite the deferoxamine, two patients went on to develop significant hepatic iron overload [<a href="#rid88">88</a>].</p><p>Monitoring for excessive iron stores in patients with SCD is discussed separately. (See  <a class="medical medical_review" href="/d/html/128123.html" rel="external">"Transfusion in sickle cell disease: Management of complications including iron overload", section on 'Excessive iron stores'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Viral hepatitis</span><span class="headingEndMark"> — </span>The reported prevalence of chronic viral hepatitis has been increased in patients with SCD compared with the general population. In addition, patients with SCD may be more susceptible to developing severe disease when acutely infected [<a href="#rid89">89</a>]. Thus, all patients with SCD and chronic liver disease should be vaccinated against hepatitis A virus and hepatitis B virus infection.</p><p class="headingAnchor" id="H23"><span class="h3">Hepatitis B virus infection</span><span class="headingEndMark"> — </span>The prevalence of chronic hepatitis B virus (HBV) infection in patients with SCD has been low in large studies from the United States (0 to 3.3 percent seropositivity for HBsAg), reflecting the low prevalence of infection in the general population [<a href="#rid10">10,90</a>]. Additionally, the rates of HBV infection in patients with SCD have been decreasing. In a study using data from the National Hospital Discharge Survey, the prevalence of HBV infection in patients with SCD was 6 percent from the time period from 1997 to 2003, while the prevalence was 0.9 percent from 2004 to 2009 [<a href="#rid91">91</a>]. In parts of the world with a higher baseline prevalence of HBV infection, higher rates of chronic HBV have been reported in patients with SCD compared with the general population. HBV immunization is discussed separately. (See  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Hepatitis C virus infection</span><span class="headingEndMark"> — </span>Antibodies against hepatitis C virus (HCV) have been detected in 10 to 20 percent of patients with SCD [<a href="#rid10">10,92,93</a>]. The risk of infection is increased in patients who have received multiple transfusions. In one study, antibody to HCV was detected more often in patients who had received &gt;10 units of packed red blood cells (23 versus 8 and 0 percent in those who received &lt;10 units or no transfusions, respectively) [<a href="#rid90">90</a>]. The natural history of chronic HCV infection and the rate of progression to cirrhosis in sickle cell anemia patients have been uncertain.</p><p>The introduction of screening blood donors for HCV infection has been associated with lower risk of transfusion-related HCV infection. In a study of 130 patients with SCD, the rate of HCV infection (as detected by anti-HCV antibody) was lower in patients who were screened in 1992 or later compared with patients screened before 1992 (22 versus 58 percent) [<a href="#rid94">94</a>]. In a study using data from the National Hospital Discharge Survey, the prevalence of HCV infection in patients with SCD was 2 percent from the time period from 1997 to 2003, while the prevalence was 3 percent from 2004 to 2009 [<a href="#rid91">91</a>].</p><p>With improved screening methods, the risk of acquiring HCV infection through blood transfusion in the United States has been extremely low (approximately 1:1,900,000 units when nucleic acid testing is employed)  (<a class="graphic graphic_figure graphicRef53650" href="/d/graphic/53650.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing"</a>.)</p><p>Management of HCV infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Other liver disorders</span><span class="headingEndMark"> — </span>A number of liver abnormalities have been described in association with SCD including hepatic infarction [<a href="#rid95">95</a>], pyogenic liver abscess [<a href="#rid96">96-99</a>], Budd-Chiari syndrome [<a href="#rid100">100,101</a>], autoimmune hepatitis [<a href="#rid102">102,103</a>], focal nodular hyperplasia [<a href="#rid104">104,105</a>], malignant histiocytosis [<a href="#rid106">106</a>], primary sclerosing cholangitis [<a href="#rid103">103</a>], and mesenteric thrombosis [<a href="#rid107">107</a>]. The etiologic role of the SCD in some of these settings is uncertain.</p><p class="headingAnchor" id="H29"><span class="h1">LIVER TRANSPLANTATION</span><span class="headingEndMark"> — </span>Liver transplantation (LT) has been infrequently performed in patients with sickle cell disease (SCD), despite estimates that &gt;25 percent of such patients carry a diagnosis of chronic liver disease [<a href="#rid108">108</a>]. Factors associated with low rates of LT have been unclear but may have been related to multiple patient comorbidities, rapid progression from liver failure to multiorgan failure, and access to LT [<a href="#rid109">109-111</a>]. In a study using the Scientific Registry of Transplant Recipients database, patients with SCD undergoing LT had higher rates of intensive care unit admission (44 versus 19 percent), pretransplant dialysis (17 versus 5 percent), and status 1 listing (26 versus 12 percent), in addition to higher Model for End-Stage Liver Disease (MELD) scores (33 versus 21 points) compared with a cohort of African American LT recipients [<a href="#rid112">112</a>]. </p><p class="headingAnchor" id="H470643838"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110843.html" rel="external">"Society guideline links: Sickle cell disease and thalassemias"</a>.)</p><p class="headingAnchor" id="H1205062745"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/d/html/132604.html" rel="external">"Patient perspective: Sickle cell disease"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The liver can be affected by several complications related to sickle cell disease (SCD) or its treatment. In addition to the vascular complications from the sickling process, patients with SCD have often received multiple transfusions, placing them at risk for complications such as iron overload and pigmented gallstones (related to effects of chronic hemolysis). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major risk factor for liver disease in patients with SCD has been receiving multiple blood transfusions, which is associated with excessive iron stores and risk of infection (hepatitis B virus and hepatitis C virus infection). (See <a class="local">'Epidemiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver biochemical and imaging abnormalities have been commonly reported in patients with SCD. (See <a class="local">'Laboratory and radiologic liver tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several clinical features of liver disease can be attributed to the sickling process, while others may be due to coexisting conditions (eg, viral hepatitis). The distinction between the two is not always clear. (See <a class="local">'Disorders associated with the sickling process'</a> above and <a class="local">'Disorders related to coexisting conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations, management, and prognosis of SCD are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/7114.html" rel="external">"Overview of the management and prognosis of sickle cell disease"</a> and  <a class="medical medical_review" href="/d/html/14519.html" rel="external">"Sickle cell disease in infancy and childhood: Routine health care maintenance and anticipatory guidance"</a>.)</p><p></p><p class="headingAnchor" id="H2050724145"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stanley L Schrier, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sickle-cell trait in a large ambulatory population. Genet Epidemiol 1987; 4:307.</a></li><li><a class="nounderline abstract_t">Johnson CS, Omata M, Tong MJ, et al. Liver involvement in sickle cell disease. Medicine (Baltimore) 1985; 64:349.</a></li><li><a class="nounderline abstract_t">Bauer TW, Moore GW, Hutchins GM. The liver in sickle cell disease. A clinicopathologic study of 70 patients. Am J Med 1980; 69:833.</a></li><li><a class="nounderline abstract_t">SONG YS. Hepatic lesions in sickle cell anemia. Am J Pathol 1957; 33:331.</a></li><li><a class="nounderline abstract_t">GREEN TW, CONLEY CL, BERTHRONG M. [The liver in sickle cell anemia]. Bull Johns Hopkins Hosp 1953; 92:99.</a></li><li><a class="nounderline abstract_t">Mills LR, Mwakyusa D, Milner PF. Histopathologic features of liver biopsy specimens in sickle cell disease. Arch Pathol Lab Med 1988; 112:290.</a></li><li><a class="nounderline abstract_t">Sheehy TW. Sickle cell hepatopathy. South Med J 1977; 70:533.</a></li><li><a class="nounderline abstract_t">Brody JI, Ryan WN, Haidar MA. Serum alkaline phosphatase isoenzymes in sickle cell anemia. JAMA 1975; 232:738.</a></li><li><a class="nounderline abstract_t">Mohamed AO, Jansson A, Ronquist G. Increased activity of 5' nucleotidase in serum of patients with sickle cell anaemia. Scand J Clin Lab Invest 1993; 53:701.</a></li><li><a class="nounderline abstract_t">DeVault KR, Friedman LS, Westerberg S, et al. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994; 18:206.</a></li><li><a class="nounderline abstract_t">Karayalcin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol Oncol 1989; 11:320.</a></li><li><a class="nounderline abstract_t">Tam DA. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol 1997; 12:19.</a></li><li><a class="nounderline abstract_t">Wright JG, Malia R, Cooper P, et al. Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels? Br J Haematol 1997; 98:627.</a></li><li><a class="nounderline abstract_t">Karayalcin G, Lanzkowsky P, Kazi AB. Zinc deficiency in children with sickle cell disease. Am J Pediatr Hematol Oncol 1979; 1:283.</a></li><li><a class="nounderline abstract_t">Yuzbasiyan-Gurkan VA, Brewer GJ, Vander AJ, et al. Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia. Am J Hematol 1989; 31:87.</a></li><li><a class="nounderline abstract_t">Silliman CC, Peterson VM, Mellman DL, et al. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship. J Lab Clin Med 1993; 122:48.</a></li><li><a class="nounderline abstract_t">Leonard MB, Zemel BS, Kawchak DA, et al. Plasma zinc status, growth, and maturation in children with sickle cell disease. J Pediatr 1998; 132:467.</a></li><li><a class="nounderline abstract_t">Rabbani P, Prasad AS. Plasma ammonia and liver ornithine transcarbamoylase activity in zinc-deficient rats. Am J Physiol 1978; 235:E203.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Hill GM, Dick RD, et al. Interactions of trace elements: clinical significance. J Am Coll Nutr 1985; 4:33.</a></li><li><a class="nounderline abstract_t">Gupta VL, Chaubey BS. Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial. J Assoc Physicians India 1995; 43:467.</a></li><li><a class="nounderline abstract_t">Prasad AS, Beck FW, Kaplan J, et al. Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD). Am J Hematol 1999; 61:194.</a></li><li><a class="nounderline abstract_t">Bao B, Prasad AS, Beck FW, et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res 2008; 152:67.</a></li><li><a class="nounderline abstract_t">Prasad AS, Abbasi AA, Rabbani P, DuMouchelle E. Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects. Am J Hematol 1981; 10:119.</a></li><li><a class="nounderline abstract_t">Zemel BS, Kawchak DA, Fung EB, et al. Effect of zinc supplementation on growth and body composition in children with sickle cell disease. Am J Clin Nutr 2002; 75:300.</a></li><li><a class="nounderline abstract_t">Brewer GJ, Hill GM, Prasad AS, Cossack ZT. Biological roles of ionic zinc. Prog Clin Biol Res 1983; 129:35.</a></li><li class="breakAll">Institute of Medicine: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2001). Available at: https://www.nap.edu/catalog/10026/dietary-reference-intakes-for-vitamin-a-vitamin-k-arsenic-boron-chromium-copper-iodine-iron-manganese-molybdenum-nickel-silicon-vanadium-and-zinc (Accessed on March 04, 2020).</li><li><a class="nounderline abstract_t">Zakaria N, Knisely A, Portmann B, et al. Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. Blood 2003; 101:101.</a></li><li><a class="nounderline abstract_t">Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996; 25:172.</a></li><li><a class="nounderline abstract_t">Rosenblate HJ, Eisenstein R, Holmes AW. The liver in sickle cell anemia. A clinical-pathologic study. Arch Pathol 1970; 90:235.</a></li><li><a class="nounderline abstract_t">Diggs LW, Ching RE. Pathology of sickle cell anemia. South Med J 1934; 27:839.</a></li><li><a class="nounderline abstract_t">Omata M, Johnson CS, Tong M, Tatter D. Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci 1986; 31:247.</a></li><li><a class="nounderline abstract_t">Shao SH, Orringer EP. Sickle cell intrahepatic cholestasis: approach to a difficult problem. Am J Gastroenterol 1995; 90:2048.</a></li><li><a class="nounderline abstract_t">Charlotte F, Bachir D, Nénert M, et al. Vascular lesions of the liver in sickle cell disease. A clinicopathological study in 26 living patients. Arch Pathol Lab Med 1995; 119:46.</a></li><li><a class="nounderline abstract_t">Aken'ova YA, Olasode BJ, Ogunbiyi JO, Thomas JO. Hepatobiliary changes in Nigerians with sickle cell anaemia. Ann Trop Med Parasitol 1993; 87:603.</a></li><li><a class="nounderline abstract_t">Barrett-Connor E. Sickle cell disease and viral hepatitis. Ann Intern Med 1968; 69:517.</a></li><li><a class="nounderline abstract_t">Wolfe JL, Anders RA, Reddoch S, et al. Longitudinal changes in liver fibrosis in children with sickle cell disease undergoing chronic transfusion therapy. Acta Gastroenterol Belg 2012; 75:419.</a></li><li><a class="nounderline abstract_t">Hankins JS, Smeltzer MP, McCarville MB, et al. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. Eur J Haematol 2010; 85:51.</a></li><li><a class="nounderline abstract_t">Ghugre NR, Wood JC. Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med 2011; 65:837.</a></li><li><a class="nounderline abstract_t">Flyer MA, Haller JO, Sundaram R. Transfusional hemosiderosis in sickle cell anemia: another cause of an echogenic pancreas. Pediatr Radiol 1993; 23:140.</a></li><li><a class="nounderline abstract_t">Siegelman ES, Outwater E, Hanau CA, et al. Abdominal iron distribution in sickle cell disease: MR findings in transfusion and nontransfusion dependent patients. J Comput Assist Tomogr 1994; 18:63.</a></li><li><a class="nounderline abstract_t">Adler DD, Glazer GM, Aisen AM. MRI of the spleen: normal appearance and findings in sickle-cell anemia. AJR Am J Roentgenol 1986; 147:843.</a></li><li><a class="nounderline abstract_t">Allali S, de Montalembert M, Brousse V, et al. Hepatobiliary Complications in Children with Sickle Cell Disease: A Retrospective Review of Medical Records from 616 Patients. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">Diggs LW. Sickle cell crises. Am J Clin Pathol 1965; 44:1.</a></li><li><a class="nounderline abstract_t">Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology 1986; 90:2013.</a></li><li><a class="nounderline abstract_t">Saltzman JR, Johnston DE. Sickle cell crisis and cocaine hepatotoxicity. Am J Gastroenterol 1992; 87:1661.</a></li><li><a class="nounderline abstract_t">Gardner K, Suddle A, Kane P, et al. How we treat sickle hepatopathy and liver transplantation in adults. Blood 2014; 123:2302.</a></li><li><a class="nounderline abstract_t">Stéphan JL, Merpit-Gonon E, Richard O, et al. Fulminant liver failure in a 12-year-old girl with sickle cell anaemia: favourable outcome after exchange transfusions. Eur J Pediatr 1995; 154:469.</a></li><li><a class="nounderline abstract_t">Rice L, Schwartz MR. Sickle cell hepatopathy with spur cell anemia. Blood 2021; 138:283.</a></li><li><a class="nounderline abstract_t">KLION FM, WEINER MJ, SCHAFFNER F. CHOLESTASIS IN SICKLE CELL ANEMIA. Am J Med 1964; 37:829.</a></li><li><a class="nounderline abstract_t">Sheehy TW, Law DE, Wade BH. Exchange transfusion for sickle cell intrahepatic cholestasis. Arch Intern Med 1980; 140:1364.</a></li><li><a class="nounderline abstract_t">OWEN DM, ALDRIDGE JE, THOMPSON RB. AN UNUSUAL HEPATIC SEQUELA OF SICKLE CELL ANEMIA: A REPORT OF FIVE CASES. Am J Med Sci 1965; 249:175.</a></li><li><a class="nounderline abstract_t">Svarch E, González A, Villaescusa R, Basanta P. Plasma exchange for acute cholestasis in homozygous sickle cell disease. Haematologia (Budap) 1986; 19:49.</a></li><li><a class="nounderline abstract_t">Morrow JD, McKenzie SW. Survival after intrahepatic cholestasis associated with sickle cell disease. J Tenn Med Assoc 1986; 79:199.</a></li><li><a class="nounderline abstract_t">Betrosian A, Balla M, Kafiri G, et al. Reversal of liver failure in sickle cell vaso-occlusive crisis. Am J Med Sci 1996; 311:292.</a></li><li><a class="nounderline abstract_t">Khan MA, Kerner JA. Reversal of hepatic and renal failure from sickle cell intrahepatic cholestasis. Dig Dis Sci 2011; 56:1634.</a></li><li><a class="nounderline abstract_t">Hatton CS, Bunch C, Weatherall DJ. Hepatic sequestration in sickle cell anaemia. Br Med J (Clin Res Ed) 1985; 290:744.</a></li><li><a class="nounderline abstract_t">Hernández P, Dorticós E, Espinosa E, et al. Clinical features of hepatic sequestration in sickle cell anaemia. Haematologia (Budap) 1989; 22:169.</a></li><li><a class="nounderline abstract_t">Lee ES, Chu PC. Reverse sequestration in a case of sickle crisis. Postgrad Med J 1996; 72:487.</a></li><li><a class="nounderline abstract_t">Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312:1033.</a></li><li class="breakAll">http://www.nhlbi.nih.gov/health-pro/guidelines/current/management-sickle-cell-disease.htm (Accessed on September 30, 2014).</li><li><a class="nounderline abstract_t">Buchanan GR, Glader BE. Benign course of extreme hyperbilirubinemia in sickle cell anemia: analysis of six cases. J Pediatr 1977; 91:21.</a></li><li><a class="nounderline abstract_t">O'Callaghan A, O'Brien SG, Ninkovic M, et al. Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion. Gut 1995; 37:144.</a></li><li><a class="nounderline abstract_t">Rennels MB, Dunne MG, Grossman NJ, Schwartz AD. Cholelithiasis in patients with major sickle hemoglobinopathies. Am J Dis Child 1984; 138:66.</a></li><li><a class="nounderline abstract_t">Adam S, Jonassaint J, Kruger H, et al. Surgical and obstetric outcomes in adults with sickle cell disease. Am J Med 2008; 121:916.</a></li><li><a class="nounderline abstract_t">Webb DK, Darby JS, Dunn DT, et al. Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Child 1989; 64:693.</a></li><li><a class="nounderline abstract_t">Sarnaik S, Slovis TL, Corbett DP, et al. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. J Pediatr 1980; 96:1005.</a></li><li><a class="nounderline abstract_t">Walker TM, Hambleton IR, Serjeant GR. Gallstones in sickle cell disease: observations from The Jamaican Cohort study. J Pediatr 2000; 136:80.</a></li><li><a class="nounderline abstract_t">Bond LR, Hatty SR, Horn ME, et al. Gall stones in sickle cell disease in the United Kingdom. Br Med J (Clin Res Ed) 1987; 295:234.</a></li><li><a class="nounderline abstract_t">Irizarry K, Rossbach HC, Ignacio JR, et al. Sickle cell intrahepatic cholestasis with cholelithiasis. Pediatr Hematol Oncol 2006; 23:95.</a></li><li><a class="nounderline abstract_t">Vasavda N, Menzel S, Kondaveeti S, et al. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 2007; 138:263.</a></li><li><a class="nounderline abstract_t">Passon RG, Howard TA, Zimmerman SA, et al. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001; 23:448.</a></li><li><a class="nounderline abstract_t">Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005; 105:968.</a></li><li class="breakAll">National Heart, Lung, and Blood Institute (US). Evidence-based management of sickle cell disease: Expert panel report, 2014. https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf.</li><li><a class="nounderline abstract_t">Wales PW, Carver E, Crawford MW, Kim PC. Acute chest syndrome after abdominal surgery in children with sickle cell disease: Is a laparoscopic approach better? J Pediatr Surg 2001; 36:718.</a></li><li><a class="nounderline abstract_t">Delatte SJ, Hebra A, Tagge EP, et al. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg 1999; 34:188.</a></li><li><a class="nounderline abstract_t">Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013; 381:930.</a></li><li><a class="nounderline abstract_t">D'Alonzo WA Jr, Heyman S. Biliary scintigraphy in children with sickle cell anemia and acute abdominal pain. Pediatr Radiol 1985; 15:395.</a></li><li><a class="nounderline abstract_t">Malone BS, Werlin SL. Cholecystectomy and cholelithiasis in sickle cell anemia. Am J Dis Child 1988; 142:799.</a></li><li><a class="nounderline abstract_t">Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 1995; 333:206.</a></li><li><a class="nounderline abstract_t">Goers T, Panepinto J, Debaun M, et al. Laparoscopic versus open abdominal surgery in children with sickle cell disease is associated with a shorter hospital stay. Pediatr Blood Cancer 2008; 50:603.</a></li><li><a class="nounderline abstract_t">Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol 1987; 78:198.</a></li><li><a class="nounderline abstract_t">Brownell A, Lowson S, Brozović M. Serum ferritin concentration in sickle cell crisis. J Clin Pathol 1986; 39:253.</a></li><li><a class="nounderline abstract_t">Kelly S, Rodeghier M, DeBaun MR. Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease. Transfusion 2020; 60:2508.</a></li><li><a class="nounderline abstract_t">Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42:81.</a></li><li><a class="nounderline abstract_t">Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78:206.</a></li><li><a class="nounderline abstract_t">Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer 2008; 50:62.</a></li><li><a class="nounderline abstract_t">Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96:76.</a></li><li><a class="nounderline abstract_t">Laulan S, Bernard JF, Boivin P. [Systematic blood transfusions in adult homozygote sickle-cell anemia. Study of 11 cases followed for 5 to 10 years]. Presse Med 1990; 19:785.</a></li><li><a class="nounderline abstract_t">Yohannan MD, Arif M, Ramia S. Aetiology of icteric hepatitis and fulminant hepatic failure in children and the possible predisposition to hepatic failure by sickle cell disease. Acta Paediatr Scand 1990; 79:201.</a></li><li><a class="nounderline abstract_t">Hasan MF, Marsh F, Posner G, et al. Chronic hepatitis C in patients with sickle cell disease. Am J Gastroenterol 1996; 91:1204.</a></li><li><a class="nounderline abstract_t">Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study. Sex Transm Infect 2012; 88:528.</a></li><li><a class="nounderline abstract_t">Jeannel D, Fretz C, Traore Y, et al. Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 1998; 55:92.</a></li><li><a class="nounderline abstract_t">al-Fawaz I, Ramia S. Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major. Arch Dis Child 1993; 69:594.</a></li><li><a class="nounderline abstract_t">Hassan M, Hasan S, Giday S, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc 2003; 95:939.</a></li><li><a class="nounderline abstract_t">Gauthier N, Cornud F, Vissuzaine C. Liver infarction in sickle cell disease. AJR Am J Roentgenol 1985; 144:1089.</a></li><li><a class="nounderline abstract_t">Chong SK, Dick MC, Howard ER, Mowat AP. Liver abscess as an unusual complication in sickle cell anemia. J Pediatr Gastroenterol Nutr 1993; 16:221.</a></li><li><a class="nounderline abstract_t">Brittain HP, De la Torre A, Willey EN. A case of sickle cell disease with an abscess arising in an infarct of the liver. Ann Intern Med 1966; 65:560.</a></li><li><a class="nounderline abstract_t">Lama M. Hepatic abscess in sickle cell anaemia: a rare manifestation. Arch Dis Child 1993; 69:242.</a></li><li><a class="nounderline abstract_t">Shulman ST, Beem MO. An unique presentation of sickle cell disease: pyogenic hepatic abscess. Pediatrics 1971; 47:1019.</a></li><li><a class="nounderline abstract_t">Sty JR. Ultrasonography: hepatic vein thrombosis in sickle cell anemia. Am J Pediatr Hematol Oncol 1982; 4:213.</a></li><li><a class="nounderline abstract_t">Attal HC, Gupta VL, Salkar HR. Budd-Chiari syndrome due to inferior vena cava obstruction in sickle cell trait. J Assoc Physicians India 1984; 32:526.</a></li><li><a class="nounderline abstract_t">el Younis CM, Min AD, Fiel MI, et al. Autoimmune hepatitis in a patient with sickle cell disease. Am J Gastroenterol 1996; 91:1016.</a></li><li><a class="nounderline abstract_t">Chuang E, Ruchelli E, Mulberg AE. Autoimmune liver disease and sickle cell anemia in children: a report of three cases. J Pediatr Hematol Oncol 1997; 19:159.</a></li><li><a class="nounderline abstract_t">Markowitz RI, Harcke HT, Ritchie WG, Huff DS. Focal nodular hyperplasia of the liver in a child with sickle cell anemia. AJR Am J Roentgenol 1980; 134:594.</a></li><li><a class="nounderline abstract_t">Heaton ND, Pain J, Cowan NC, et al. Focal nodular hyperplasia of the liver: a link with sickle cell disease? Arch Dis Child 1991; 66:1073.</a></li><li><a class="nounderline abstract_t">Wong WS, Sherman NE, Moss AA. Malignant histiocytosis in a patient with sickle cell anemia: CT findings. J Comput Assist Tomogr 1983; 7:908.</a></li><li><a class="nounderline abstract_t">Arnold KE, Char G, Serjeant GR. Portal vein thrombosis in a child with homozygous sickle-cell disease. West Indian Med J 1993; 42:27.</a></li><li class="breakAll">Shondelle M, Wilson Frederick P, Hulihan M, et al. Prevalence of sickle cell disease among medicare fee-for-service beneficiaries, age 18-75 years, in 2016, Centers for Medicare and Medicaid. https://www.cms.gov/About-CMS/Agency-Information/OMH/Downloads/Data-Highlight-15-Sickle-Cell-Disease.pdf.</li><li><a class="nounderline abstract_t">Hurtova M, Bachir D, Lee K, et al. Transplantation for liver failure in patients with sickle cell disease: challenging but feasible. Liver Transpl 2011; 17:381.</a></li><li><a class="nounderline abstract_t">Mustian MN, Shelton BA, MacLennan PA, et al. Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates. Transplantation 2019; 103:1425.</a></li><li><a class="nounderline abstract_t">Sharpe CC, Suddle A, Stuart-Smith S. An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease. Transplantation 2023; 107:596.</a></li><li><a class="nounderline abstract_t">Hogen R, Kim M, Lee Y, et al. Liver Transplantation in Patients with Sickle Cell Disease in the United States. J Surg Res 2020; 255:23.</a></li></ol></div><div id="topicVersionRevision">Topic 3589 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3666437" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Age and prevalence of sickle-cell trait in a large ambulatory population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4033412" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Liver involvement in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446549" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The liver in sickle cell disease. A clinicopathologic study of 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13402890" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatic lesions in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13009339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [The liver in sickle cell anemia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3345126" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Histopathologic features of liver biopsy specimens in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/870977" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sickle cell hepatopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1173174" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Serum alkaline phosphatase isoenzymes in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903822" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Increased activity of 5' nucleotidase in serum of patients with sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8034915" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hepatitis C in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2782560" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Plasma protein C levels in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010791" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Protein C and protein S activity in sickle cell disease and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9332318" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/543518" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Zinc deficiency in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2735321" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Net renal tubular reabsorption of zinc in healthy man and impaired handling in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320490" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544903" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Plasma zinc status, growth, and maturation in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686166" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Plasma ammonia and liver ornithine transcarbamoylase activity in zinc-deficient rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3886759" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Interactions of trace elements: clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8713219" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10398312" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18674741" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6786094" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815322" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of zinc supplementation on growth and body composition in children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6361779" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Biological roles of ionic zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6361779" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Biological roles of ionic zinc.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393551" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8878778" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Variability in hepatic iron concentration measurement from needle-biopsy specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5451891" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The liver in sickle cell anemia. A clinical-pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pathology of sickle cell anemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3948629" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pathological spectrum of liver diseases in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485022" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sickle cell intrahepatic cholestasis: approach to a difficult problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802553" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vascular lesions of the liver in sickle cell disease. A clinicopathological study in 26 living patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122922" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatobiliary changes in Nigerians with sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4175136" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sickle cell disease and viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402085" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Longitudinal changes in liver fibrosis in children with sickle cell disease undergoing chronic transfusion therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20374273" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21337413" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8516039" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transfusional hemosiderosis in sickle cell anemia: another cause of an echogenic pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8282886" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Abdominal iron distribution in sickle cell disease: MR findings in transfusion and nontransfusion dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3489394" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MRI of the spleen: normal appearance and findings in sickle-cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31540390" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hepatobiliary Complications in Children with Sickle Cell Disease: A Retrospective Review of Medical Records from 616 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sickle cell crises</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516788" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hepatobiliary system in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442696" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sickle cell crisis and cocaine hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565828" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : How we treat sickle hepatopathy and liver transplantation in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7671945" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fulminant liver failure in a 12-year-old girl with sickle cell anaemia: favourable outcome after exchange transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292331" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sickle cell hepatopathy with spur cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14237437" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : CHOLESTASIS IN SICKLE CELL ANEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7425771" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Exchange transfusion for sickle cell intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14257309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : AN UNUSUAL HEPATIC SEQUELA OF SICKLE CELL ANEMIA: A REPORT OF FIVE CASES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3721321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Plasma exchange for acute cholestasis in homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3713167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Survival after intrahepatic cholestasis associated with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659557" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Reversal of liver failure in sickle cell vaso-occlusive crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21267779" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reversal of hepatic and renal failure from sickle cell intrahepatic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3918737" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hepatic sequestration in sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2583596" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical features of hepatic sequestration in sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8796214" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Reverse sequestration in a case of sickle crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25203083" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/874660" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Benign course of extreme hyperbilirubinemia in sickle cell anemia: analysis of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672666" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691315" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cholelithiasis in patients with major sickle hemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823864" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Surgical and obstetric outcomes in adults with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658854" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gall stones in Jamaican children with homozygous sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7373460" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636979" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Gallstones in sickle cell disease: observations from The Jamaican Cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3115390" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gall stones in sickle cell disease in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16651237" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sickle cell intrahepatic cholestasis with cholelithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17593033" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11878580" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388579" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : UGT1A1 variation and gallstone formation in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388579" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : UGT1A1 variation and gallstone formation in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11329573" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acute chest syndrome after abdominal surgery in children with sickle cell disease: Is a laparoscopic approach better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022169" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acute chest syndrome in the postoperative sickle cell patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352054" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4058965" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Biliary scintigraphy in children with sickle cell anemia and acute abdominal pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3381786" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cholecystectomy and cholelithiasis in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791837" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17480009" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Laparoscopic versus open abdominal surgery in children with sickle cell disease is associated with a shorter hospital stay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3120472" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958215" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Serum ferritin concentration in sickle cell crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32812667" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416302" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3120473" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457853" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10891433" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140170" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : [Systematic blood transfusions in adult homozygote sickle-cell anemia. Study of 11 cases followed for 5 to 10 years].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2157327" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aetiology of icteric hepatitis and fulminant hepatic failure in children and the possible predisposition to hepatic failure by sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651171" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Chronic hepatitis C in patients with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22628662" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598927" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257183" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Decline in hepatitis B infection in sickle cell anaemia and beta thalassaemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14620705" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hepatitis C virus in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3885690" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Liver infarction in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450394" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Liver abscess as an unusual complication in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5911748" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A case of sickle cell disease with an abscess arising in an infarct of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215532" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hepatic abscess in sickle cell anaemia: a rare manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5141745" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : An unique presentation of sickle cell disease: pyogenic hepatic abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7114404" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Ultrasonography: hepatic vein thrombosis in sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6511734" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Budd-Chiari syndrome due to inferior vena cava obstruction in sickle cell trait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633541" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autoimmune hepatitis in a patient with sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149749" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Autoimmune liver disease and sickle cell anemia in children: a report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6766634" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Focal nodular hyperplasia of the liver in a child with sickle cell anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929517" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Focal nodular hyperplasia of the liver: a link with sickle cell disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886145" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Malignant histiocytosis in a patient with sickle cell anemia: CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8503211" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Portal vein thrombosis in a child with homozygous sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8503211" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Portal vein thrombosis in a child with homozygous sickle-cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21445921" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Transplantation for liver failure in patients with sickle cell disease: challenging but feasible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418427" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Ethnic and Age Disparities in Outcomes Among Liver Transplant Waitlist Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36210501" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : An Overview of Solid Organ Transplantation in Patients With Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32540577" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Liver Transplantation in Patients with Sickle Cell Disease in the United States.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
